×
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
NYSEAMERICAN:PTN

Palatin Technologies Stock Forecast, Price & News

$0.31
+0.03 (+10.83%)
(As of 06/24/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.29
$0.31
50-Day Range
N/A
52-Week Range
$0.26
$0.96
Volume
291,829 shs
Average Volume
1.04 million shs
Market Capitalization
$71.13 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.50
30 days | 90 days | 365 days | Advanced Chart

Receive PTN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Palatin Technologies and its competitors with MarketBeat's FREE daily newsletter.

PTN Stock Forecast (MarketRank)

Overall MarketRank

1.78 out of 5 stars

Analyst Opinion: 3.5Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
Palatin Technologies logo

About Palatin Technologies (NYSEAMERICAN:PTN)

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, an NPR-A and NPR-binder to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. The company was incorporated in 1986 and is based in Cranbury, New Jersey.

PTN Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NYSEAMERICAN:PTN
Employees
26
Year Founded
N/A

Company Calendar

Last Earnings
5/17/2022
Today
6/26/2022
Fiscal Year End
6/30/2022

Price Target and Rating

Average Stock Price Forecast
$3.50
High Stock Price Forecast
$5.00
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
+1,040.1%
Consensus Rating
Buy
Rating Score (0-4)
3
Research Coverage
2 Analysts

Profitability

Net Income
$-33.60 million
Pretax Margin
-14,141.92%

Debt

Sales & Book Value

Annual Sales
$120 thousand
Book Value
$0.22 per share

Miscellaneous

Free Float
212,375,000
Market Cap
$71.13 million
Optionable
Not Optionable
Beta
0.79














Palatin Technologies Frequently Asked Questions

Should I buy or sell Palatin Technologies stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Palatin Technologies in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Palatin Technologies stock.
View analyst ratings for Palatin Technologies
or view top-rated stocks.

What is Palatin Technologies' stock price forecast for 2022?

2 brokerages have issued 1 year target prices for Palatin Technologies' stock. Their PTN stock forecasts range from $2.00 to $5.00. On average, they anticipate Palatin Technologies' share price to reach $3.50 in the next twelve months. This suggests a possible upside of 1,040.1% from the stock's current price.
View analysts' price targets for Palatin Technologies
or view top-rated stocks among Wall Street analysts.

How has Palatin Technologies' stock price performed in 2022?

Palatin Technologies' stock was trading at $0.43 at the beginning of 2022. Since then, PTN stock has decreased by 28.6% and is now trading at $0.3070.
View the best growth stocks for 2022 here
.

Are investors shorting Palatin Technologies?

Palatin Technologies saw a decrease in short interest during the month of May. As of May 31st, there was short interest totaling 2,030,000 shares, a decrease of 16.1% from the May 15th total of 2,420,000 shares. Based on an average daily volume of 831,400 shares, the short-interest ratio is currently 2.4 days. Approximately 1.0% of the company's stock are short sold.
View Palatin Technologies' Short Interest
.

How were Palatin Technologies' earnings last quarter?

Palatin Technologies, Inc. (NYSEAMERICAN:PTN) announced its quarterly earnings results on Tuesday, May, 17th. The biopharmaceutical company reported ($0.03) EPS for the quarter, hitting analysts' consensus estimates of ($0.03). The biopharmaceutical company had revenue of $0.22 million for the quarter, compared to the consensus estimate of $0.58 million. During the same quarter in the prior year, the business posted ($0.02) earnings per share.
View Palatin Technologies' earnings history
.

Who are Palatin Technologies' key executives?

Palatin Technologies' management team includes the following people:
  • Dr. Carl Spana Ph.D., Co-Founder, Pres, CEO & Director (Age 60, Pay $924.5k)
  • Mr. Stephen T. Wills CPA, CPA, MST, CFO, COO, Exec. VP, Treasurer & Sec. (Age 65, Pay $851.93k)
  • Burns McClellan, VP of Investor Relations
  • Mr. Stephen A. Slusher Esq., Chief Legal Officer
  • Dr. Michael B. Raizman M.D., Chief Medical Officer
  • Mr. James E. Hattersley, Sr. VP of Bus. Devel. (Age 62)
  • Mr. John Dodd Ph.D., Sr. VP of Preclinical Devel.
  • Mr. Robert Jordan, Sr. VP of Program Operations

What other stocks do shareholders of Palatin Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Palatin Technologies investors own include (XXII), Heat Biologics (HTBX), Sorrento Therapeutics (SRNE), Trevena (TRVN), Alliqua Biomedical (ALQA), Catalyst Pharmaceuticals (CPRX), AVEO Pharmaceuticals (AVEO), ImmunoGen (IMGN), TherapeuticsMD (TXMD) and Actinium Pharmaceuticals (ATNM).

What is Palatin Technologies' stock symbol?

Palatin Technologies trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "PTN."

Who are Palatin Technologies' major shareholders?

Palatin Technologies' stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (4.13%), State Street Corp (0.33%) and Connective Portfolio Management LLC (0.02%). Company insiders that own Palatin Technologies stock include Carl Spana, Joseph Stanley Hull, Robert K Deveer Jr and Stephen T Wills.
View institutional ownership trends for Palatin Technologies
.

Which institutional investors are buying Palatin Technologies stock?

PTN stock was acquired by a variety of institutional investors in the last quarter, including State Street Corp, Connective Portfolio Management LLC, and Vanguard Group Inc..
View insider buying and selling activity for Palatin Technologies
or or view top insider-buying stocks.

How do I buy shares of Palatin Technologies?

Shares of PTN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Palatin Technologies' stock price today?

One share of PTN stock can currently be purchased for approximately $0.31.

How much money does Palatin Technologies make?

Palatin Technologies (NYSEAMERICAN:PTN) has a market capitalization of $71.13 million and generates $120 thousand in revenue each year. The biopharmaceutical company earns $-33.60 million in net income (profit) each year or ($0.150010) on an earnings per share basis.

How many employees does Palatin Technologies have?

Palatin Technologies employs 26 workers across the globe.

How can I contact Palatin Technologies?

Palatin Technologies' mailing address is 4B Cedarbrook Dr, CRANBURY, NJ 08512-3641, United States. The official website for Palatin Technologies is www.palatin.com. The biopharmaceutical company can be reached via phone at (609) 495-2200, via email at [email protected], or via fax at 609-495-2202.

This page (NYSEAMERICAN:PTN) was last updated on 6/26/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.